Wells Fargo Starts YM BioSciences (YMI) at Outperform; Undervalued Based on CYT387's Future Potential
Tweet
Share
E-mailGet Alerts YMI Hot Sheet
Price: $2.94 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wells Fargo initiates coverage on YM BioSciences (NYSE: YMI) with a Outperform. $4-5 valuation range.
Wells analyst says, "YMI's lead compound, CYT387 ('387), is a Jak inhibitor in phase II for myeloproliferative diseases (MPDs) such as myelofibrosis (MF). Jak inhibitors have gained recent attention due to profound benefits observed with the most advanced drug in the space, INCY/NVS's ruxolitinib. Based on early data and feedback from expert physicians, we believe '387 has the most promising profile of any mid-stage Jak inhibitor for MPDs. Although YMI is several years behind INCY/NVS, interim data have suggested a potential benefit for '387 on anemia responses, which, if confirmed in further studies, would provide an important differentiator. Regardless of whether anemia benefits ultimately appear as strong as in the interim data, we believe additional phase II results throughout 2011 will validate that '387 is a legitimate contender in the evolving Jak inhibitor area. Shares have appreciated since initial data were reported in 2010, but we believe YMI remains undervalued on a risk/reward basis and expect evolving '387 data to drive further upside potential."
For more ratings news on YM BioSciences click here and for the rating history of YM BioSciences click here.
Shares of YM BioSciences closed at $2.60 yesterday.
Wells analyst says, "YMI's lead compound, CYT387 ('387), is a Jak inhibitor in phase II for myeloproliferative diseases (MPDs) such as myelofibrosis (MF). Jak inhibitors have gained recent attention due to profound benefits observed with the most advanced drug in the space, INCY/NVS's ruxolitinib. Based on early data and feedback from expert physicians, we believe '387 has the most promising profile of any mid-stage Jak inhibitor for MPDs. Although YMI is several years behind INCY/NVS, interim data have suggested a potential benefit for '387 on anemia responses, which, if confirmed in further studies, would provide an important differentiator. Regardless of whether anemia benefits ultimately appear as strong as in the interim data, we believe additional phase II results throughout 2011 will validate that '387 is a legitimate contender in the evolving Jak inhibitor area. Shares have appreciated since initial data were reported in 2010, but we believe YMI remains undervalued on a risk/reward basis and expect evolving '387 data to drive further upside potential."
For more ratings news on YM BioSciences click here and for the rating history of YM BioSciences click here.
Shares of YM BioSciences closed at $2.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD (AMD) to offer senior notes in four parts
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
